BioSpace News Archive

Magnolia Medical Technologies, Inc., announced today that it has entered into an endorsed company agreement with MHA Solutions, a subsidiary of the Mississippi Hospital Association (MHA), and Healthcare Providers Insurance (HPIC),

Alethiomics, a drug discovery company focused on developing targeted therapies to treat a family of blood cancers called myeloproliferative neoplasms, launched today, backed by £6m seed financing from Oxford Science Enterprises.

Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, received approval for AVT02 (100 mg/mL), the company’s high concentration biosimilar to Humira® (adalimumab), from the European Commission (EC) on Nov. 15.

Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Gregory Adams, Ph.D., Chief Scientific Officer, will be presenting on Thursday, December 16th at 8:30am PST at the Antibody Engineering & Therapeutics Conference.

Ascend, a leading dialysis testing laboratory, U.S. Renal Care, and researchers at Stanford University School of Medicine have completed a study of nearly 5,000 patients receiving dialysis to determine longitudinal antibody-based response and risk for breakthrough infection after SARS-CoV-2 vaccination.

Bristol Myers Squibb announced that Orencia® was approved by the US. FDA for the prophylaxis, or prevention, of acute graft versus host disease, in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced that the first patients have been enrolled in the Phase 1 study of PF614-MPARTM, the first product utilizing the Company’s MPARTM platform designed to reduce opioid overdose.

Alpha Teknova, Inc., a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, announced that it will join the Nasdaq Biotechnology Index® effective prior to market open on Monday, December 20, 2021.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the submission of a New Drug Application to the Ministry of Health, Labour and Welfare in Japan for its COVID-19 vaccine by its partner Takeda Pharmaceutical Company Limited.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it entered into a lease agreement to expand its headquarters in South San Francisco, California.